{"id":7325,"date":"2024-04-18T16:43:20","date_gmt":"2024-04-18T16:43:20","guid":{"rendered":"https:\/\/neuropediatoolkit.org\/?p=7325"},"modified":"2026-11-01T07:40:10","modified_gmt":"2026-11-01T07:40:10","slug":"nirsevimab-en-neurologia-pediatrica","status":"publish","type":"post","link":"https:\/\/neuropediatoolkit.org\/en\/nirsevimab-en-neurologia-pediatrica\/","title":{"rendered":"Nirsevimab in pediatric neurology."},"content":{"rendered":"<h2>Mechanism of Action and Anatomy-Physiology of Nirsevimab in Pediatric Neurology<\/h2>\n<p>Nirsevimab is an intravenous immunoglobulin that works by inhibiting the function of the CD22 protein on B lymphocytes, reducing excessive inflammatory responses to viral infections. This mechanism allows for a reduction in the severity of viral respiratory infections, particularly in patients with complex neurological conditions.<\/p>\n<p>Physiologically, CD22 is a molecule that facilitates the differentiation and maturation of B lymphocytes, playing a role in immune responses. In patients with congenital metabolic disorders, neuromuscular diseases, and genetic syndromes, this altered immune response can lead to severe respiratory infections. Nirsevimab, by inactivating CD22, improves immune homeostasis and reduces unnecessary inflammation.<\/p>\n<h2>Indications for Treatment with Nirsevimab in Pediatric Neurology<\/h2>\n<h3>Congenital Metabolic Disorders<\/h3>\n<p>Nirsevimab is particularly beneficial in patients with congenital metabolic disorders, such as citrullinemia or glucose-6-phosphate dehydrogenase (G6PD) deficiency. These patients have an increased risk of respiratory infections due to the accumulation of toxic metabolites and muscle weakness, respectively. Preventing respiratory infections can improve the patient's quality of life and overall prognosis.<\/p>\n<h3>Neuromuscular Diseases<\/h3>\n<p>Neuromuscular diseases, such as Duchenne muscular dystrophy, carry a high risk of respiratory infections due to muscle weakness and respiratory insufficiency. Nirsevimab may prevent these infections, improving patients' functional independence and quality of life.<\/p>\n<h3>Genetic Syndromes with Relevant Respiratory Problems<\/h3>\n<p>Certain genetic syndromes, such as Down syndrome, are also associated with an increased risk of respiratory infections. In these cases, nirsevimab may reduce the frequency and severity of infections, enabling more effective and less invasive management of respiratory complications.<\/p>\n<h3>Down syndrome<\/h3>\n<p>In Down syndrome, the risk of respiratory infections is significantly higher due to muscle weakness, esophageal obstruction, and respiratory insufficiency. Nirsevimab can prevent these infections, improving overall health and quality of life in patients.<\/p>\n<h3>Patients in Palliative Care<\/h3>\n<p>Nirsevimab can be used in patients with advanced neurological diseases, where preventing respiratory infections may prolong life and improve quality of life. In these cases, Nirsevimab is a valuable tool for preventing potentially fatal complications.<\/p>\n<h2>Diagnostic Criteria and Clinical Algorithm<\/h2>\n<p>Nirsevimab use should be considered in patients with a significant risk of severe viral respiratory infections. Factors such as patient age, presence of neurological conditions, neuromuscular status, and presenting symptoms are crucial in determining whether a patient is a candidate for treatment.<\/p>\n<h3>Risk Factors<\/h3>\n<p>Individual risk assessment includes factors such as age (children under 2 years are more vulnerable), neuromuscular weakness, respiratory insufficiency, and the presence of respiratory symptoms. The clinical algorithm is based on these factors to identify patients who will benefit most from treatment with Nirsevimab.<\/p>\n<h3>Interpretation of Results<\/h3>\n<p>Nirsevimab use should be regularly monitored to assess its effectiveness. Monitoring of respiratory symptoms, frequency of respiratory infections, and overall patient progression is recommended. Comparing results with normal values and identifying trends can guide therapeutic decisions.<\/p>\n<h2>Practical Recommendations for Consultation<\/h2>\n<ul>\n<li>Comprehensive individual risk assessment.<\/li>\n<li>Consider use in patients with neuromuscular diseases or genetic syndromes that increase the risk of severe viral respiratory infections.<\/li>\n<li>Perform periodic follow-up to monitor treatment effectiveness and adjust indications as necessary.<\/li>\n<li>Assessment of treatment tolerance and drug response.<\/li>\n<li>Detailed clinical documentation for future follow-up.<\/li>\n<\/ul>\n<h2>Vaccine Campaigns<\/h2>\n<p>Nirsevimab can be administered up to 24 months of age, corresponding to two vaccination campaigns. The first dose is given at 2 months of age and the second at 6 months of age. Administering the doses separately ensures an adequate immune response.<\/p>","protected":false},"excerpt":{"rendered":"<p>Mechanism of Action and Anatomophysiology of Nirsevimab in Pediatric Neurology Nirsevimab is an intravenous immunoglobulin that acts by inhibiting the function of the CD22 protein in B lymphocyte cells, reducing the excessive inflammatory response to viral infections. This mechanism allows a reduction in the severity of viral respiratory infections, particularly in those patients... <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/neuropediatoolkit.org\/en\/nirsevimab-en-neurologia-pediatrica\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> \"Nirsevimab in pediatric neurology.\"<\/span><\/a><\/p>","protected":false},"author":1,"featured_media":7348,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[18],"tags":[],"class_list":["post-7325","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-vacunas","entry"],"_links":{"self":[{"href":"https:\/\/neuropediatoolkit.org\/en\/wp-json\/wp\/v2\/posts\/7325","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/neuropediatoolkit.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/neuropediatoolkit.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/neuropediatoolkit.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/neuropediatoolkit.org\/en\/wp-json\/wp\/v2\/comments?post=7325"}],"version-history":[{"count":7,"href":"https:\/\/neuropediatoolkit.org\/en\/wp-json\/wp\/v2\/posts\/7325\/revisions"}],"predecessor-version":[{"id":9078,"href":"https:\/\/neuropediatoolkit.org\/en\/wp-json\/wp\/v2\/posts\/7325\/revisions\/9078"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/neuropediatoolkit.org\/en\/wp-json\/wp\/v2\/media\/7348"}],"wp:attachment":[{"href":"https:\/\/neuropediatoolkit.org\/en\/wp-json\/wp\/v2\/media?parent=7325"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/neuropediatoolkit.org\/en\/wp-json\/wp\/v2\/categories?post=7325"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/neuropediatoolkit.org\/en\/wp-json\/wp\/v2\/tags?post=7325"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}